세계 혈액 악성 종양 시장 규모는 2024년 651억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 1,295억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 7.55%를 보일 것으로 예측했습니다. 혈액암 유병률 증가, 유전자 프로파일에 맞춘 표적치료제 및 면역치료제 채택 증가, 혈액암의 새로운 치료법에 초점을 맞춘 바이오의약품 파이프라인의 확대는 시장 성장을 가속하는 주요 요인 중 일부입니다.
혈액암 유병률 증가
혈액암 발병률 증가와 새로운 치료법 개발이 혈액 악성 종양 시장의 성장을 주도하고 있습니다. Globocan 2020에 따르면, 백혈병의 추정 발병률은 아시아가 가장 높으며, 2020년 230,650명이 진단을 받았고, 유럽 100,020명, 북미 67,784명 순으로 나타났습니다. 이처럼 전 세계적으로 백혈병의 높은 발병률이 혈액 악성 종양 시장의 성장을 가속할 것으로 예측됩니다. 마찬가지로, Global Cancer Observatory에 따르면, 2020년 북미에서 67,784건의 백혈병과 35,318건의 다발성 골수종으로 추정되는 다발성 골수종 사례가 보고되었습니다. 백혈병 림프종 협회에 따르면, 2021년 미국에서 백혈병을 앓고 있거나 관해 상태인 사람은 총 39만 7,501명으로 추산됩니다. 따라서, 시장에서 혈액암 환자의 현저한 증가는 예측 기간 동안 혈액 악성 종양 시장 가치를 견인할 것으로 예측됩니다.
제품 출시, 파트너십, 제휴 증가
많은 기업들이 시장에서의 입지를 강화하기 위해 신제품 출시, 파트너십 형성, 협력관계 증진, M&A 등 다양한 전략적 이니셔티브를 시행하고 있습니다. 이는 혈액 악성 종양 시장 전망에 긍정적인 영향을 미치고 있습니다. 예를 들어, 2020년 10월, 아스트라제네카 파마 인디아(AstraZeneca Pharma India)는 다양한 유형의 백혈병(백혈병(CLL) 및 소림프구성 림프종) 치료에 사용되는 아카라브루티닙 100mg 캡슐을 Calquence라는 브랜드로 출시할 것이라고 발표했습니다. 마찬가지로 2024년 1월, 타타기념병원은 인도 최초의 백혈병 경구용 화학요법제를 개발했습니다. 이 획기적인 개발은 암 치료, 특히 급성림프모구백혈병(ALL)과 같은 혈액 악성 종양에 혁명을 가져올 것이며, 기존의 정제를 대체할 수 있는 보다 정확하고 어린이 친화적인 치료법을 제공하게 될 것입니다. 이러한 기술 혁신은 향후 몇 년 동안 혈액 악성 종양 시장 수요를 증가시킬 것으로 예측됩니다.
제품 승인 증가
다양한 규제 당국이 혈액암 치료제를 승인하고 있으며, 이는 시장 전체에 밝은 전망을 가져다주고 있습니다. 예를 들어, 2020년 9월 미국 FDA는 브리스톨 마이어스 스퀴브(Bristol Myers Squibb)의 아자시티딘(Onureg) 300mg 정제 CC-486을 급성 골수성 백혈병 성인 환자의 치료 지속을 위해 승인했습니다. 마찬가지로 2021년 3월, 사노피 SA는 재발성 또는 불응성 다발성 골수종 환자를 위한 살클리사(성분명: 이사툭시맙)와 칼필루조밉 및 덱사메타손 병용요법에 대한 미국 FDA 승인을 획득했습니다. 이에 따라 TG테라퓨틱스(TG Therapeutics Inc.)는 2021년 2월 재발성/불응성 변연부 림프종(MZL) 성인 환자 및 재발성/불응성 여포형 림프종(FL) 성인 환자 치료제로 1일 1회 경구용 포스포이노시타이드3키나아제(PI3K) 델타 및 카제인키나아제1( CK1) 엡실론 억제제인 UKONIQ(엄브렐리시브)의 미국 FDA 신속 승인을 획득했습니다. 혈액암 치료제로 승인된 약물의 수가 크게 증가하면서 혈액암 시장 가치를 높이고 있습니다.
The global hematologic malignancies market size reached USD 65.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 129.5 Billion by 2033, exhibiting a growth rate (CAGR) of 7.55% during 2025-2033. Growing prevalence of blood cancer, increasing adoption of targeted therapies and immunotherapies tailored to genetic profiles, and expansion of biopharmaceutical pipelines focusing on novel treatments for hematologic cancers are some of the key factors driving the growth of the market.
Rising Prevalence of Blood Cancer
Escalating incidences of blood cancer and a growing emphasis on the development of new treatments are primarily driving the growth in the hematologic malignancies market. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America. Thus, the high incidence of leukemia worldwide is expected to drive the hematologic malignancies market growth. Similarly, according to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. According to the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, a prominent rise in blood cancer cases in the market is expected to propel the hematologic malignancies market value over the forecasted period.
Growing Number of Product Launches, Partnerships, and Collaborations
Numerous companies are implementing diverse strategic initiatives such as launching new products, forming partnerships, fostering collaborations, and engaging in mergers and acquisitions to enhance their market presence. This, in turn, is positively impacting the hematologic malignancies market outlook. For instance, in October 2020, AstraZeneca Pharma India announced the launch of Acalabrutinib 100 mg capsules, which are used for the treatment of various types of leukemias (leukemia (CLL) and small lymphocytic lymphoma) under the brand name Calquence. Similarly, in January 2024, Tata Memorial Hospital developed India's first oral chemo drug for Leukaemia. This groundbreaking development is poised to revolutionize cancer treatment, specifically hematologic malignancies like Acute Lymphoblastic Leukaemia (ALL), providing a more precise and child-friendly alternative to traditional tablets. Such innovations are projected to augment the hematologic malignancies market demand in the coming years.
Increasing Product Approvals
Various concerned regulatory authorities are increasingly approving hematologic malignancies drugs, which is creating a positive outlook for the overall market. For instance, in September 2020, the US FDA approved Bristol Myers Squibb's azacytidine (Onureg) 300 mg tablets, CC-486, to continue treating adult patients with acute myeloid leukemia. Similarly, in March 2021, Sanofi SA received US FDA approval for its Sarclisa (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma. In line with this, in February 2021, TG Therapeutics Inc. received the US FDA accelerated approval for its UKONIQ (umbralisib), an oral, once-daily inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1 (CK1) epsilon for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with relapsed or refractory follicular lymphoma (FL). Significant growth in number of approved drugs for treating blood cancer is propelling the hematologic malignancies market value.
The hematologic malignancies market report has provided a detailed breakup and analysis of the market based on the type. This includes leukemia, lymphoma, multiple myeloma, and others.
Leukemia is a type of hematologic malignancy, also known as blood cancer, that originates in the bone marrow and affects the production of blood cells. The rising cases of leukemia across the globe are bolstering the hematologic malignancies market share. According to Globocan 2020, the estimated incidence of leukemia was the highest in Asia, with 230,650 cases diagnosed in 2020, followed by 100,020 cases in Europe and 67,784 cases in North America.
Furthermore, the significant rise in the multiple myeloma market is a clear indication of the need for increased research and development. For instance, according to the Global Cancer Observatory, in 2020, nearly 35,318 cases of multiple myeloma were reported in the North American region. This rise in multiple myeloma cases underscores the importance of your work and is positively influencing the hematologic malignancies market price trends.
As per the hematologic malignancies market overview by IMARC, for most types of blood cancers, chemotherapy is the common treatment. The large patient pool and the increasing incidence of blood cancers are the major drivers augmenting the need for chemotherapy. For instance, in June 2019, the United States Food and Drug Administration granted approval to Polivy to be used in combination with the chemotherapy drug bendamustine and rituximab to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies.
The hematologic malignancies market research report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, diagnostics centers, research centers, and others.
Hospitals are primary end users in the hematologic malignancies market, providing diagnosis, treatment, and ongoing care for patients with blood cancers, such as leukemia, lymphoma, and myeloma. They offer a range of specialized services, including chemotherapy, radiation therapy, stem cell transplantation, and supportive care. Hospitals also serve as centers for clinical trials and research, driving advancements in treatment options and patient outcomes.
Diagnostics centers are essential for early detection and monitoring of hematologic malignancies through a variety of tests, including blood tests, bone marrow biopsy, imaging studies, and genetic testing. These centers provide accurate diagnostic services, enabling healthcare providers to initiate timely treatment strategies. Diagnostics centers often collaborate closely with hospitals and oncology clinics to ensure comprehensive patient care and management throughout the treatment journey.
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa.
The hematologic malignancies market shows strong growth globally. In North America, the growth can be attributed to the advanced healthcare infrastructure and high incidence rates. Europe follows with significant investments in research and development. Asia-Pacific is emerging rapidly, driven by increasing healthcare expenditure and improving access to advanced treatments, fostering market expansion.
Besides this, hematologic malignancies market statistics indicates that the presence of key players, the high prevalence of blood cancer patients, established healthcare infrastructure, and the availability of branded drugs in North America and Asia Pacific countries are positively impacting the hematologic malignancies industry. According to the Global Cancer Observatory, in 2020, nearly 67,784 cases of leukemia and an estimated 35,318 cases of multiple myeloma were reported in the North American region. As per the Leukemia and Lymphoma Society, in 2021, an estimated combined total of 397,501 people in the United States were living with or in remission from leukemia in the United States. Thus, the increasing number of blood cancer cases in the region is a major driving factor for the growth of the market. Besides this, hematologic malignancies market forecast by IMARC indicates that beneficial government initiatives and an increase in the number of research partnerships are further contributing to the market growth. For instance, in December 2020, the Leukemia and Lymphoma Society (LLS) initiated a collaboration to form alliances with leading cancer institutions and foundations to co-fund nearly US$ 17 Million in research grants to progress the research in finding effective treatment options for patients with leukemia, lymphoma, myeloma, and other blood cancers.